Lest this become the "Jurgen Gotz solo" stage, I'd like to sound my three notes:
First, to thank Lon Schneider for his most enlightening dissection of the problems surrounding the Alzhemed trial. To be honest, while I had hoped for the best, I am not really surprised by the outcome of the Phase III because Alzhemed could not be labeled a "disease-modifying" compound - at the most pathology-modifying.
Second, to recommend the study by Santa-Maria and the group of Jesus Avila, for indicating another problem with the compound, totally overlooked - or rather invisible - in amyloid model mice! Actually, we do not understand tau dynamics well enough yet to predict if the tramiprosate effect on tau will be a problem or not, but it needs to be studied. The study stresses once again the importance of realizing that AD is invariably amyloid and tau pathology combined and the pre-clinical models must reflect that fact.
Third, to congratulate AlzForum for bringing this story and showing us all sides of it.
View all comments by Fred Van Leuven